A phase III study of JNP-0101 in patients with overactive bladder

Trial Profile

A phase III study of JNP-0101 in patients with overactive bladder

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2016

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Sponsors Juniper Pharmaceuticals
  • Most Recent Events

    • 14 Jan 2016 New trial record
    • 11 Jan 2016 This trial is expected to begin in the first half of 2017. This development program is intended to satisfy the regulatory requirements for approval and will follow the 505(b)(2) regulatory pathway, according to a Juniper Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top